旭輝(0884.HK)發行首單25億元CMBS,利率4.75%
11月26日,旭輝集團首單交易所CMBS(物業資產支持證券)成功發行。本次發行總金額25億元,最終發行票面利率4.75%。
這是繼近期以5.25%的歷史最低利率成功發行3.5億美元優先票據之後,旭輝再次以行業同期較低的利率水平成功發債,體現了公司主動穩健的財務策略和融資渠道的持續多元化,並將帶動平均融資成本繼續走低。
今年中報顯示,2020上半年,旭輝控股加權平均融資成本降至5.6%,淨負債率降至63.2%,現金短債比2.4倍,財務狀況良好。CFO楊欣曾表示,相信今年旭輝的融資成本將進一步下降。
同日,國際知名評級機構穆迪將旭輝控股的企業評級從“Ba3”調升至“Ba2”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.